Anavex Outlines Corporate Milestones, Drug Advancement Plans for 2008

Geneva, Switzerland — January 22, 2008 — Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL) reported today that the company achieved significant development of its lead drug candidates and in the growth of its management and scientific teams during 2007.  The company further disclosed key corporate objectives for 2008.“This past year has been extremely successful for…

Anavex Advances Drug Candidate for Treatment of Alzheimer’s Disease

Results from animal model testing demonstrate ANAVEX 1-41 has significant neuroprotective and anti-amnesic benefits Geneva, Switzerland — November 28, 2007 — Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL) is pleased to announce promising developments with ANAVEX 1-41, the company’s lead drug candidate for Alzheimer’s disease. In recent pre-clinical animal studies, ANAVEX 1-41 prevented oxidative stress,…

Anavex Strengthens Board of Directors

Geneva, Switzerland — December 17, 2007 — Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL) today announced the appointment of Dr. Cameron Durrant to its Board of Directors. Dr. Durrant is currently Worldwide Vice President of Virology Global Strategic Marketing at Johnson & Johnson (NYSE: JNJ). “ANAVEX is both pleased and privileged to welcome Dr. Durrant…

ANAVEX 7-1037 Demonstrates Chemotherapeutic Potential Without Toxic Side Effects for the Treatment of Colorectal Cancer, Other Types of Solid Tumors

Geneva, Switzerland — December 11, 2007 — Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL) today announced that ANAVEX 7-1037 has been shown to kill human HCT116 colon cancer cells in advanced pre-clinical studies.  In addition, ANAVEX 7-1037 demonstrated its ability to significantly suppress tumor growth in immune-deficient mice.  ANAVEX 7-1037 is the company’s lead drug…

Anavex Advances Drug Candidates for Treatment of Epilepsy

Results in epilepsy animal models demonstrate that ANAVEX 2-73 and its active metabolite ANAVEX 19-144 have potent anticonvulsant, anti-amnesic and neuroprotective properties Geneva, Switzerland — December 6, 2007 — Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL) today announced promising developments with ANAVEX 2-73 and ANAVEX 19-144, the company’s lead drug candidates to treat epilepsy. During…

Anavex Life Sciences Engages Primoris Group to Provide Investor Relations Services

Geneva, Switzerland — November 2, 2007 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCBB: AVXL) is pleased to announce that it has engaged Primoris Group Inc. to provide investor relations services to the Company.  Primoris Group is a full-service investor relations firm based in Toronto,Canada.Primoris Group will implement a communications program to support…

Annual General Meeting of the Shareholders of Anavex Life Sciences Corp.

The Annual General Meeting of Anavex Life Sciences Corp. shareholders was held on May 25, 2007 in Geneva, Switzerland Geneva, Switzerland — June 5, 2007 — Anavex Life Sciences Corp. (the “Company”) (OTCBB:AVXL) a biopharmaceutical company, announced the results of its recently held Annual General Meeting. At the Annual General Meeting shareholders  elected  Dr. Panos Kontzalis, Mr.…